Calcium, magnesium, potassium, and sodium oxybates

(Xywav®)

Xywav®

Drug updated on 11/28/2023

Dosage FormSolution (oral; 0.5 g/mL)
Drug ClassCentral nervous system depressant
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
  • Treatment of idiopathic hypersomnia (IH) in adults.

Product Monograph / Prescribing Information

Document TitleYearSource
Xywav (calcium, magnesium, potassium, and sodium oxybates) Prescribing Information.2023Jazz Pharmaceuticals, Inc., Palo Alto, CA

Randomized Controlled Trials

Clinical Practice Guidelines